Division of Oncology/Hematology, Department of Internal Medicine, College of Medicine, Korea University, 148 Gurodong-ro, Guro-gu, Seoul 08308, Republic of Korea.
Biomed Res Int. 2018 Jan 17;2018:6074808. doi: 10.1155/2018/6074808. eCollection 2018.
Currently, the growing population of the elderly is one of biggest problems in terms of increase in geriatric diseases. Lack of data from large prospective studies on geriatric breast cancer patients often makes it difficult for clinicians to make treatments decisions for them. Because both benefit and risk of treatment should be taken into account, treatment is usually determined considering life expectancy or comorbidities in elderly patients. Treatment of breast cancer is differentiated according to histologic classifications, and hormone therapy is even adopted for patients with metastatic breast cancer if tumor tissue expresses hormone receptors. Endocrine therapy can offer great benefit to elderly patients considering its equivalent efficacy to chemotherapy with fewer toxicities if it is appropriately used. Aromatase inhibitors are usually prescribed agents in hormone therapy for elderly breast cancer patients due to their physiology after menopause. Here, endocrine therapy for elderly patients with breast cancer in neoadjuvant, adjuvant, and palliative setting is reviewed along with predictive adverse events resulting from the use of hormone agents.
目前，老年人口的增长是老年疾病增加方面最大的问题之一。由于缺乏关于老年乳腺癌患者的大型前瞻性研究数据，临床医生往往难以为他们做出治疗决策。因为治疗的获益和风险都应该考虑在内，所以老年患者的治疗通常是根据预期寿命或合并症来决定的。乳腺癌的治疗根据组织学分类进行区分，如果肿瘤组织表达激素受体，则即使是转移性乳腺癌患者也会采用激素治疗。如果激素治疗能够合理使用，它的毒性比化疗少，但疗效却相当，因此它可以为老年患者带来很大的益处。由于老年女性绝经后的生理特点，芳香化酶抑制剂通常被用于老年乳腺癌患者的激素治疗中。本文回顾了激素治疗在新辅助、辅助和姑息治疗中老年乳腺癌患者中的应用，以及激素治疗的应用所导致的不良事件的预测。
